JP2009520503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520503A5 JP2009520503A5 JP2008547621A JP2008547621A JP2009520503A5 JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5 JP 2008547621 A JP2008547621 A JP 2008547621A JP 2008547621 A JP2008547621 A JP 2008547621A JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla4
- composition
- molecule
- domain
- glycosylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 230000004988 N-glycosylation Effects 0.000 claims 9
- 230000013595 glycosylation Effects 0.000 claims 9
- 238000006206 glycosylation reaction Methods 0.000 claims 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 4
- 229920001542 oligosaccharide Polymers 0.000 claims 4
- 150000002482 oligosaccharides Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000013627 low molecular weight specie Substances 0.000 claims 1
- 238000003468 luciferase reporter gene assay Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75215005P | 2005-12-20 | 2005-12-20 | |
| US75226705P | 2005-12-20 | 2005-12-20 | |
| US60/752,267 | 2005-12-20 | ||
| US60/752,150 | 2005-12-20 | ||
| US84954306P | 2006-10-05 | 2006-10-05 | |
| US60/849,543 | 2006-10-05 | ||
| PCT/US2006/049074 WO2007076032A2 (en) | 2005-12-20 | 2006-12-19 | Compositions and methods for producing a composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Division JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009520503A JP2009520503A (ja) | 2009-05-28 |
| JP2009520503A5 true JP2009520503A5 (https=) | 2010-02-18 |
| JP5096369B2 JP5096369B2 (ja) | 2012-12-12 |
Family
ID=38218674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547621A Active JP5096369B2 (ja) | 2005-12-20 | 2006-12-19 | 組成物および組成物の製造方法 |
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10508144B2 (https=) |
| EP (2) | EP2253644B1 (https=) |
| JP (2) | JP5096369B2 (https=) |
| KR (2) | KR101391457B1 (https=) |
| CN (1) | CN106589132B (https=) |
| AU (2) | AU2006330922B2 (https=) |
| BR (2) | BRPI0622251A2 (https=) |
| CA (2) | CA2634760C (https=) |
| CY (1) | CY1114887T1 (https=) |
| DK (2) | DK1969007T3 (https=) |
| EA (1) | EA017765B1 (https=) |
| ES (2) | ES2433092T3 (https=) |
| HR (1) | HRP20130975T1 (https=) |
| IL (2) | IL192098A (https=) |
| MX (1) | MX336807B (https=) |
| NO (1) | NO20082716L (https=) |
| NZ (1) | NZ597215A (https=) |
| PE (1) | PE20080556A1 (https=) |
| PL (2) | PL2253644T3 (https=) |
| PT (2) | PT2253644E (https=) |
| SI (2) | SI2253644T1 (https=) |
| TW (2) | TWI423986B (https=) |
| WO (1) | WO2007076032A2 (https=) |
| ZA (1) | ZA200805301B (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1969007T3 (da) | 2005-12-20 | 2013-11-25 | Bristol Myers Squibb Co | Sammensætninger og fremgangsmåder til fremstilling af en sammensætning |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| EP2450368A1 (en) | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| SI4269578T1 (sl) | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| RU2011118341A (ru) | 2008-10-06 | 2012-11-20 | 3-Д Матрикс, Лтд. (Jp) | Агент для окклюзии тканей |
| CN101995476B (zh) * | 2009-08-10 | 2013-07-03 | 中国医学科学院北京协和医院 | 临床化学检验用液体质控血清 |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP2507627A2 (en) | 2009-12-04 | 2012-10-10 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
| CN102762585B (zh) | 2010-02-12 | 2016-01-20 | DPx控股有限公司 | 单一单元抗体纯化 |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| US20120121574A1 (en) * | 2010-11-15 | 2012-05-17 | Luciano Polonelli | Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| US8679767B2 (en) * | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| US20150038362A1 (en) * | 2012-02-27 | 2015-02-05 | Biogen Idec Ma Inc. | High-Throughput Method For Sialic Acid Quantitation |
| US20150140589A1 (en) * | 2012-04-22 | 2015-05-21 | Perfinity Biosciences, Inc. | Automated protein digestion, recovery, and analysis |
| US9926365B2 (en) * | 2012-06-29 | 2018-03-27 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
| WO2014008400A2 (en) * | 2012-07-06 | 2014-01-09 | 3-D Matrix, Inc. | Fill-finish process for peptide solutions |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| BR112016019510A2 (pt) | 2014-03-10 | 2017-10-24 | 3 D Matrix Ltd | esterilização e filtração de composições de peptídeos |
| RU2016139369A (ru) | 2014-03-10 | 2018-04-10 | 3-Д Матрикс, Лтд. | Композиции самоорганизующихся пептидов |
| US20170042972A1 (en) | 2014-04-25 | 2017-02-16 | Chetan KARYEKAR | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| JP6948942B2 (ja) * | 2014-10-15 | 2021-10-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用 |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| EP3307890A1 (en) | 2015-06-10 | 2018-04-18 | Board of Regents, The University of Texas System | Use of exosomes for the treatment of disease |
| TWI579030B (zh) * | 2015-12-15 | 2017-04-21 | Ｃｇ生物技術有限公司 | 分離細胞之容器、系統及方法 |
| US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US10613081B2 (en) * | 2016-11-27 | 2020-04-07 | Alireza Palangi | Quality control system and kit for automated ELISA devices |
| WO2018229802A1 (en) * | 2017-06-16 | 2018-12-20 | Ge Healthcare Bio-Sciences Ab | Method for predicting outcome of and modelling of a process in a bioreactor |
| CN109385401A (zh) * | 2017-08-10 | 2019-02-26 | 北京泰德制药股份有限公司 | 一种表达重组蛋白的cho细胞的培养方法 |
| FI3684381T3 (fi) * | 2017-09-21 | 2023-01-13 | Solunulkoisten vesikkelien tuotanto yksisolususpensiossa käyttämällä kemiallisesti määriteltyä soluviljelyn elatusainetta | |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP7102734B2 (ja) | 2018-01-09 | 2022-07-20 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法及び装置 |
| EP3781941B1 (en) * | 2018-04-20 | 2026-01-14 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions |
| WO2020088645A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| US11965900B2 (en) * | 2018-11-09 | 2024-04-23 | Wyatt Technology, Llc | Indicating a status of an analytical instrument on a screen of the analytical instrument |
| CN114041049B (zh) * | 2019-06-14 | 2026-03-17 | 安捷伦科技有限公司 | 改善dmb标记的唾液酸的荧光信号的方法和试剂盒 |
| WO2021019295A1 (en) * | 2019-07-26 | 2021-02-04 | Jan Remmereit | Sialic acid for use in the treatment of psoriasis |
| CN110554107B (zh) * | 2019-08-14 | 2022-06-10 | 上海应用技术大学 | 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法 |
| EP4062176B1 (en) | 2019-11-21 | 2024-05-22 | Bristol-Myers Squibb Company | Label-free n-glycan quantification methods |
| CN111398308B (zh) * | 2020-03-27 | 2023-01-17 | 上海健康医学院 | 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统 |
| JP7415771B2 (ja) | 2020-04-24 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| JP7314859B2 (ja) | 2020-04-30 | 2023-07-26 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| JP7415783B2 (ja) * | 2020-05-12 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| US20230323422A1 (en) * | 2020-08-14 | 2023-10-12 | Bristol-Myers Squibb Company | Method of making protein |
| KR20230042125A (ko) * | 2020-08-14 | 2023-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질에 대한 제조 공정 |
| CN112198302B (zh) * | 2020-10-25 | 2022-12-16 | 中铁二局第一工程有限公司 | 一种细集料含泥量快速检测方法及测量工具 |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| CA3113278C (en) * | 2021-03-25 | 2025-08-12 | Lumex Instruments Canada (0890278 B.C. Ltd.) | Device for electrophoretic analysis of multicomponent liquid samples |
| WO2022208550A1 (en) * | 2021-03-31 | 2022-10-06 | Dr. Reddy's Laboratories Limited | Cell culture process for fusion protein composition |
| CN113241192B (zh) * | 2021-05-18 | 2023-06-20 | 武汉大学中南医院 | 一种证据合成方法和计算机设备 |
| JP7600875B2 (ja) * | 2021-06-01 | 2024-12-17 | 株式会社島津製作所 | 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法 |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| US20240400612A1 (en) * | 2021-09-28 | 2024-12-05 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
| EP4408856A4 (en) * | 2021-09-28 | 2025-11-12 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PROTEIN PURIFICATION |
| KR20240125949A (ko) * | 2021-12-16 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 바이러스 불활성화를 위한 세제 |
| JP2025016812A (ja) * | 2021-12-16 | 2025-02-05 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
| WO2023112000A2 (en) * | 2021-12-17 | 2023-06-22 | Kashiv Biosciences, Llc | An improved method for separation of low molecular weight proteins |
| WO2023178329A1 (en) * | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| CN116467264B (zh) * | 2023-04-14 | 2025-11-28 | 阿里健康科技(中国)有限公司 | Rf2文件的生成方法、装置、设备和存储介质 |
| US12461955B2 (en) * | 2023-09-08 | 2025-11-04 | Salesforce, Inc. | Integration flow generation using large language models |
| CN117044627B (zh) * | 2023-10-11 | 2023-12-15 | 中国科学院昆明植物研究所 | 一种高山植物塔黄的组培快繁及离体保存方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460694A (en) * | 1981-03-26 | 1984-07-17 | University Of Miami | Bovine glycoproteins and use in diagnosing infectious mononucleosis |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| WO1993010260A1 (en) * | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| CA2171832C (en) * | 1993-09-15 | 2001-01-02 | Harutyun Eran | Alpha1-acid glycoprotein purification process and product |
| US5451660A (en) * | 1993-12-13 | 1995-09-19 | Genentech, Inc. | Method for purifying polypeptides |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| JPH10501815A (ja) | 1994-06-07 | 1998-02-17 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 抗原特異的ｔ細胞応答の阻害方法 |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| AU729459B2 (en) | 1996-11-15 | 2001-02-01 | Genentech Inc. | Purification of neurotrophins |
| DE69738075T2 (de) | 1996-11-27 | 2008-05-21 | Genentech, Inc., South San Francisco | Affinitätsreinigung von polypeptiden an einer protein a-matrix |
| ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030124614A1 (en) | 1997-08-29 | 2003-07-03 | Brighams And Womens Hospital Inc. | Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof |
| DK1036179T4 (da) | 1997-12-03 | 2014-03-31 | Roche Diagnostics Gmbh | Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| EP1500661A1 (en) | 1998-06-01 | 2005-01-26 | Genetech, Inc. | Separation of protein monomers from aggregates by use of ion-exchange chromatography |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6358703B1 (en) * | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6506598B1 (en) | 1999-04-26 | 2003-01-14 | Genentech, Inc. | Cell culture process |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| AU4951501A (en) * | 2000-03-27 | 2001-10-08 | Genetics Inst | Methods for purifying highly anionic proteins |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| CN101255192A (zh) * | 2000-05-26 | 2008-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4突变体分子及其应用 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| MXPA02012157A (es) | 2000-06-09 | 2003-06-06 | Bristol Myers Squibb Co | Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos. |
| US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| EP1360290A2 (en) | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP1935427B1 (en) * | 2000-07-03 | 2018-03-07 | Bristol-Myers Squibb Company | Uses of soluble CTLA4 mutant molecules |
| US6358265B1 (en) | 2000-07-18 | 2002-03-19 | Specialized Health Products, Inc. | Single-step disposable safety lancet apparatus and methods |
| CA2436139A1 (en) | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| US7304033B2 (en) | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| ATE363541T1 (de) * | 2002-03-26 | 2007-06-15 | Lek Tovarna Farmacevtskih | Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen |
| CA2480121C (en) | 2002-03-27 | 2012-02-28 | Immunex Corporation | Methods for increasing polypeptide production |
| CA2481658A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| CA2482042A1 (en) | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
| TR200302265T1 (tr) | 2002-06-19 | 2004-08-23 | Eös Eczacibaşi Özgün Ki̇myasal Ürünler San. Ve Ti̇c. A.Ş. | Sübstitiye fenil eterlerin üretimi için proses |
| EP1543106B1 (en) * | 2002-07-15 | 2007-04-11 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| MXPA05006522A (es) * | 2002-12-23 | 2006-02-17 | Bristol Myers Squibb Co | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina. |
| MXPA05006523A (es) * | 2002-12-23 | 2005-08-26 | Squibb Bristol Myers Co | Procesos de cultivo de celulas de mamiferos para la produccion de proteinas. |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US7118222B2 (en) * | 2003-05-12 | 2006-10-10 | Seiko Epson Corporation | Optical device and protector |
| EP1639014B1 (en) * | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| SG144925A1 (en) | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| US7427659B2 (en) * | 2003-10-24 | 2008-09-23 | Amgen Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
| RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| DK1969007T3 (da) | 2005-12-20 | 2013-11-25 | Bristol Myers Squibb Co | Sammensætninger og fremgangsmåder til fremstilling af en sammensætning |
| US8476239B2 (en) | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
| SI2061803T2 (sl) | 2006-08-28 | 2023-01-31 | Ares Trading S.A. | Postopek za čiščenje proteinov, ki vsebujejo FC |
| WO2008025747A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-fusion proteins |
-
2006
- 2006-12-19 DK DK06848052.4T patent/DK1969007T3/da active
- 2006-12-19 DK DK10153282.8T patent/DK2253644T3/da active
- 2006-12-19 HR HRP20130975TT patent/HRP20130975T1/hr unknown
- 2006-12-19 CN CN201610350033.8A patent/CN106589132B/zh active Active
- 2006-12-19 PE PE2006001650A patent/PE20080556A1/es not_active Application Discontinuation
- 2006-12-19 EA EA200801571A patent/EA017765B1/ru not_active IP Right Cessation
- 2006-12-19 JP JP2008547621A patent/JP5096369B2/ja active Active
- 2006-12-19 PT PT101532828T patent/PT2253644E/pt unknown
- 2006-12-19 SI SI200631693T patent/SI2253644T1/sl unknown
- 2006-12-19 ES ES06848052T patent/ES2433092T3/es active Active
- 2006-12-19 EP EP10153282.8A patent/EP2253644B1/en not_active Revoked
- 2006-12-19 EP EP06848052.4A patent/EP1969007B1/en not_active Revoked
- 2006-12-19 CA CA2634760A patent/CA2634760C/en active Active
- 2006-12-19 PL PL10153282T patent/PL2253644T3/pl unknown
- 2006-12-19 CA CA2836123A patent/CA2836123C/en active Active
- 2006-12-19 SI SI200631696T patent/SI1969007T1/sl unknown
- 2006-12-19 ES ES10153282.8T patent/ES2439641T3/es active Active
- 2006-12-19 KR KR1020117029336A patent/KR101391457B1/ko active Active
- 2006-12-19 KR KR1020087017540A patent/KR101398713B1/ko active Active
- 2006-12-19 TW TW101148477A patent/TWI423986B/zh active
- 2006-12-19 NZ NZ597215A patent/NZ597215A/xx unknown
- 2006-12-19 BR BRPI0622251-0A patent/BRPI0622251A2/pt not_active Application Discontinuation
- 2006-12-19 AU AU2006330922A patent/AU2006330922B2/en active Active
- 2006-12-19 US US12/086,786 patent/US10508144B2/en active Active
- 2006-12-19 BR BRPI0620178-4A patent/BRPI0620178B1/pt active IP Right Grant
- 2006-12-19 PT PT68480524T patent/PT1969007E/pt unknown
- 2006-12-19 TW TW095147641A patent/TWI398520B/zh active
- 2006-12-19 PL PL06848052T patent/PL1969007T4/pl unknown
- 2006-12-19 WO PCT/US2006/049074 patent/WO2007076032A2/en not_active Ceased
-
2008
- 2008-06-12 IL IL192098A patent/IL192098A/en active IP Right Grant
- 2008-06-13 NO NO20082716A patent/NO20082716L/no not_active Application Discontinuation
- 2008-06-18 ZA ZA2008/05301A patent/ZA200805301B/en unknown
- 2008-06-20 MX MX2012006495A patent/MX336807B/es unknown
-
2009
- 2009-12-21 JP JP2009289570A patent/JP5097194B2/ja active Active
-
2010
- 2010-11-08 AU AU2010241289A patent/AU2010241289B2/en active Active
-
2013
- 2013-12-10 IL IL229904A patent/IL229904A0/en unknown
-
2014
- 2014-01-14 CY CY20141100030T patent/CY1114887T1/el unknown
-
2018
- 2018-07-23 US US16/042,977 patent/US10941189B2/en active Active
- 2018-07-24 US US16/044,217 patent/US10808021B2/en active Active
-
2020
- 2020-11-25 US US17/105,358 patent/US12030923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009520503A5 (https=) | ||
| Espevik et al. | The involvement of CD14 in stimulation of cytokine production by uronic acid polymers | |
| Davies et al. | Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis | |
| US9394362B2 (en) | IL-21 antibodies and methods of making or using the antibodies | |
| US10858425B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| US6399078B1 (en) | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases | |
| EP2279001B1 (en) | Inhibitors of gm-csf and il-17 for therapy | |
| TW201302791A (zh) | 抗ｐｓｇｌ－１抗體及其之應用 | |
| RU2656162C2 (ru) | Антитела к интерлейкину 6 и их применение | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| EP1154799A2 (en) | Biotinylated-chemokine antibody complexes | |
| AU2015275926A1 (en) | Oral composition of anti-TNF alpha antibodies | |
| TW201520226A (zh) | 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體 | |
| JP2018502603A (ja) | 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途 | |
| ITMI960358A1 (it) | Citochine modificate per l'uso in terapia | |
| JP2023145581A (ja) | インターロイキン－２３受容体のペプチド阻害剤の組成物 | |
| Duan et al. | A synthetic MD-2 mimetic peptide attenuates lipopolysaccharide-induced inflammatory responses in vivo and in vitro | |
| Al Faruque et al. | Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis | |
| JP2014198711A (ja) | Ｃｔ阻害４価ペプチドおよびコレラ治療薬 | |
| ITMI20011833A1 (it) | Agenti che regolano la permeabilita' vascolare | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| CN120118174A (zh) | Ccr4的胞外段重组蛋白及其用途 | |
| Ducreux et al. | The inhibitory potencies of monoclonal antibodies to the macrophage adhesion molecule sialoadhesin are greatly increased following PEGylation | |
| TH111657A (th) | องค์ประกอบและวิธีการสำหรับการผลิตองค์ประกอบ | |
| Jancin | IL-17A blocker shows early promise for psoriasis |